JP2024507533A5 - - Google Patents

Info

Publication number
JP2024507533A5
JP2024507533A5 JP2023550277A JP2023550277A JP2024507533A5 JP 2024507533 A5 JP2024507533 A5 JP 2024507533A5 JP 2023550277 A JP2023550277 A JP 2023550277A JP 2023550277 A JP2023550277 A JP 2023550277A JP 2024507533 A5 JP2024507533 A5 JP 2024507533A5
Authority
JP
Japan
Prior art keywords
rabies virus
recombinant
approximately
functional variant
genome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023550277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024507533A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/017075 external-priority patent/WO2022178307A1/en
Publication of JP2024507533A publication Critical patent/JP2024507533A/ja
Publication of JP2024507533A5 publication Critical patent/JP2024507533A5/ja
Pending legal-status Critical Current

Links

JP2023550277A 2021-02-19 2022-02-18 遺伝子治療のための組み換え狂犬病ウイルス Pending JP2024507533A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163151542P 2021-02-19 2021-02-19
US63/151,542 2021-02-19
US202163241989P 2021-09-08 2021-09-08
US63/241,989 2021-09-08
PCT/US2022/017075 WO2022178307A1 (en) 2021-02-19 2022-02-18 Recombinant rabies viruses for gene therapy

Publications (2)

Publication Number Publication Date
JP2024507533A JP2024507533A (ja) 2024-02-20
JP2024507533A5 true JP2024507533A5 (cg-RX-API-DMAC10.html) 2025-02-26

Family

ID=80953580

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023550277A Pending JP2024507533A (ja) 2021-02-19 2022-02-18 遺伝子治療のための組み換え狂犬病ウイルス

Country Status (7)

Country Link
US (1) US20220290164A1 (cg-RX-API-DMAC10.html)
EP (1) EP4263825A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024507533A (cg-RX-API-DMAC10.html)
KR (1) KR20230158476A (cg-RX-API-DMAC10.html)
AU (1) AU2022224054A1 (cg-RX-API-DMAC10.html)
CA (1) CA3208612A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022178307A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3850088A4 (en) 2018-09-07 2023-07-19 Beam Therapeutics, Inc. Compositions and methods for improving base editing
KR20210055733A (ko) 2018-09-07 2021-05-17 빔 테라퓨틱스, 인크. 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
JP7646552B2 (ja) 2019-01-31 2025-03-17 ビーム セラピューティクス インク. 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ
US12600971B2 (en) 2019-02-13 2026-04-14 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
WO2020168135A1 (en) 2019-02-13 2020-08-20 Beam Therapeutics Inc. Compositions and methods for treating alpha-1 antitrypsin deficiency
US12594301B2 (en) 2019-09-27 2026-04-07 Beam Therapeutics Inc. Compositions and methods for treatment of liquid cancers
AU2021347359A1 (en) 2020-09-25 2023-05-18 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
CN118369429A (zh) * 2021-09-08 2024-07-19 比姆医疗股份有限公司 病毒引导rna递送
US20240327802A1 (en) * 2023-02-01 2024-10-03 Beam Therapeutics Inc. Chimeric pseudotyped recombinant rabies virus
AU2024384487A1 (en) * 2023-11-20 2026-06-04 Beam Therapeutics Inc. Compositions and methods for altering complement activation
CN119033805B (zh) * 2024-08-12 2025-07-22 华南农业大学 靶向抑制狂犬病病毒G基因和/或L基因的siRNA在制备抑制狂犬病的药物中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
JPH0825869B2 (ja) 1987-02-09 1996-03-13 株式会社ビタミン研究所 抗腫瘍剤包埋リポソ−ム製剤
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6503717B2 (en) 1999-12-06 2003-01-07 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
JP2003514564A (ja) 1999-11-24 2003-04-22 エムシーエス マイクロ キャリア システムズ ゲーエムベーハー 核局在化シグナルまたはタンパク質導入領域の多量体を含むポリペプチド、および分子を細胞内へ移入するためのその使用法
AU2001250774B2 (en) 2000-02-08 2005-01-27 Sangamo Biosciences, Inc. Cells expressing zinc finger proteins for drug discovery
EP1434862A4 (en) * 2001-07-20 2005-04-06 Univ Georgia Res Found ATTENUATED TOLL WUTVIRUS WITH NUCLEOPROTEIN MUTATION AT THE PHOSPHORYLATION CENTER FOR VACCINATION AGAINST FOLLOW-UP AND GENE THERAPY IN THE CNS
HUE041426T2 (hu) 2009-11-02 2019-05-28 Univ Washington Terápiás nukleáz-készítmények és eljárások
WO2011163446A2 (en) * 2010-06-24 2011-12-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Pan-lyssavirus vaccines against rabies
WO2012106490A1 (en) * 2011-02-03 2012-08-09 The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Multivalent vaccines for rabies virus and filoviruses
PL3346983T3 (pl) 2015-09-11 2020-11-16 Wm. Wrigley Jr. Company Synergistyczne działanie przeciwbakteryjne ekstraktu kory magnolii i L-argininy, estru N-alfa-etylowo-lauroilowego na bakterie występujące w ślinie
CN105139759B (zh) 2015-09-18 2017-10-10 京东方科技集团股份有限公司 一种拼接屏
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
WO2017200790A1 (en) * 2016-05-20 2017-11-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Real-time reverse transcriptase-polymerase chain reaction assay with modified probe for the diagnosis of rabies viruses and other lyssaviruses
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
GB201706945D0 (en) * 2017-05-02 2017-06-14 Medical Res Council Self-inactivating viral vector
WO2019013258A1 (ja) * 2017-07-11 2019-01-17 国立大学法人 東京大学 光制御性のウイルスタンパク質、その遺伝子、及びその遺伝子を含むウイルスベクター
CN109929839B (zh) * 2017-12-18 2021-02-12 华东师范大学 拆分型单碱基基因编辑系统及其应用
US11453893B2 (en) * 2018-08-30 2022-09-27 California Institute Of Technology RNA-based delivery systems with levels of control

Similar Documents

Publication Publication Date Title
EP3684925B1 (en) Non-integrating dna vectors for the genetic modification of cells
AU760770B2 (en) Episomally relicating vector, its preparation and use
Liu et al. Cationic Liposome-mediated Intravenous Gene Delivery (∗)
DE69429260T2 (de) Adenovirale vektoren tierischen ursprungs und ihre verwendung bei der gentherapie
Mulia et al. Advances in the development and the applications of nonviral, episomal vectors for gene therapy
Ohwada et al. Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver
Zeng et al. High-efficiency stable gene transfer of adenovirus into mammalian cells using ionizing radiation
NZ315295A (en) Ovine adenovirus oav287 and its use in gene therapy
US6881724B2 (en) Use of magnesium (Mg2+) for the preparation of a therapeutic composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy
JP2024533396A5 (cg-RX-API-DMAC10.html)
Acsadi et al. Interferons impair early transgene expression by adenovirus-mediated gene transfer in muscle cells
Kaneda Improvements in gene therapy technologies
JP2026513742A (ja) 合成回路及びその使用
JPH02502605A (ja) 遺伝子発現の刺激方法
US20020142393A1 (en) Episomally replicating vector, its preparation and use
DE69810925T2 (de) Verwendung eines kationischen Polymer zur Herstellung von Nukleinsäure-Komplexe und verwandte Zusammensetzungen
Narumi et al. Adenovirus vector-mediated perforin expression driven by a glucocorticoid-inducible promoter inhibits tumor growth in vivo
US6723708B2 (en) Use of lithium (Li+) for the preparation of a composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy
Bogomolova et al. Genetic engineering approaches to the development of modern therapeutics
HK40031637B (en) Non-integrating dna vectors for the genetic modification of cells
HK40031637A (en) Non-integrating dna vectors for the genetic modification of cells
Lund Journal of Experimental Biochemistry & Physiology
HK40060164A (en) Rna site-directed editing using artificially constructed rna editing enzymes and related uses
Wang et al. 465. In Vivo Selection of Genetically Modified Primary Human Hematopoietic Cells Using a Cell Growth Switch
KANEDA DEVELOPMENT OF HVJ-LIPOSOMES AND CANCER GENE THERAPY